Jun 29 2023
Earlier this year, the FDA made a major decision to reduce animal testing and promote alternative models for preclinical testing
Alternative models are now in a fair competition for preclinical testing and validation of new drug candidates, for oncology and other pathologies, and are actively promoted by the FDA to Replace, Reduce and Refine (3Rs) animal testing.
By removing the obligation for animal testing, this clears the way forward for alternative models to take the lead. It opens the way for economic and scientific incentives to bringing these models to maturity and acceptance within the wider Biotech and Pharma industries.
Many of these robust models, such INOVOTION’s CAM model, provide the same results as the mouse, faster and at a lower cost, with higher reliability.
Jun 3 - May 6
2024
Come and join us at the BIO International Convention
Come and join us at the BIO International Convention – June 3 – 6th, San Diego! INOVOTION is excited to meet and engage with the biotech industrial and research community. This annual international event is […]
May 30
2024
Jean Viallet giving a conference at Grenoble CEA
Jean Viallet of INOVOTION will be giving a conference at Grenoble CEA on May 30th at 11:00AM, entitled: “A unique platform for in vivo, 3Rs-compliant evaluation of oncology & immuno-oncology drug candidates and biomaterial compatibility” […]
May 16-17
2024
Come and join us at the Meet2Win
Come and join us at the Meet2Win – May 16 – 17th Bordeaux! INOVOTION is very proud to be sponsoring the Meet2Win Oncology Partnering Convention, May 16-17, 2024 in Bordeaux, France, organized by MATWIN. Entirely dedicated […]
